Morlat P, Chene G, Ragnaud J M, Mercie P, Grobost F, Bernard N, Lacoste D, Beylot J, Aubertin J
Internal Medicine Department, Saint André Hospital, Bordeaux, France.
Pathol Biol (Paris). 1996 Oct;44(8):716-9.
We studied the evolution of Tumor Necrosis Factor-alpha serum concentration (TNF-alpha) and CD4+ lymphocyte counts (CD4+) in a pilot cohort study of HIV-infected patients during the first year of zidovudine therapy. Data on 17 patients remaining asymptomatic during the one-year follow-up period (non progressors) were analysed. Serum samples were obtained at entry and at each follow-up visit (1, 3, 6, 9 and 12 months). TNF-alpha was quantified in pg/ml using a very sensitive radioimmunoassay (Medgenix). All patients had increased TNF-alpha at entry (median: 26.4 pg/ml). TNF-alpha decreased significantly as soon as the first month of therapy (median: 16 pg/ml). A steady state was then observed until Month 6 (median: 17.5 pg/ml), from which a slow increase appeared, without reaching the initial level (median at Month 9: 21.3, at Month 12: 19.8). During the same time, less sustained changes in CD4+ lymphocytes count and beta-2 microglobulin level were observed. The results of this pilot study suggest that, during HIV infection treated course, TNF-alpha could potentially be an additional surrogate marker to CD4+ lymphocyte count.
在一项关于齐多夫定治疗的首年对HIV感染患者的初步队列研究中，我们研究了肿瘤坏死因子-α血清浓度（TNF-α）和CD4 +淋巴细胞计数（CD4 +）的变化情况。分析了17例在一年随访期内仍无症状的患者（非进展者）的数据。在入组时以及每次随访（1、3、6、9和12个月）时采集血清样本。使用非常灵敏的放射免疫分析法（Medgenix）以pg/ml为单位对TNF-α进行定量。所有患者在入组时TNF-α均升高（中位数：26.4 pg/ml）。治疗第一个月时TNF-α就显著下降（中位数：16 pg/ml）。然后观察到直到第6个月处于稳定状态（中位数：17.5 pg/ml），此后开始缓慢上升，但未达到初始水平（第9个月中位数：21.3，第12个月中位数：19.8）。在此期间，观察到CD4 +淋巴细胞计数和β-2微球蛋白水平的变化不太持续。这项初步研究的结果表明，在HIV感染治疗过程中，TNF-α可能潜在地成为CD4 +淋巴细胞计数之外的另一个替代标志物。
